Abaloparatide
Also known as: Abaloparatide acetate, abaloparatide‑sen, ABL, ABP‑125, BA058, PTHrP analogue, Tymlos
Source Abaloparatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Abaloparatide is a prescription, subcutaneously administered analogue of parathyroid hormone‑related protein (PTHrP) approved for the treatment of osteoporosis. It belongs to the class of bone‑forming (anabolic) agents and is recommended for individuals at very high risk of fracture, such as those with recent vertebral fractures or low bone mineral density.
Mechanism of Action
Abaloparatide binds to the parathyroid hormone 1 (PTH1) receptor on osteoblasts and osteocytes, mimicking the action of endogenous PTHrP. Intermittent activation of this receptor preferentially stimulates bone formation pathways, increasing osteoblast activity and bone mineral density while having a lesser effect on bone resorption compared with continuous exposure.
What the Research Shows
Clinical guidance reviews note that anabolic agents, including abaloparatide, are appropriate for very high‑risk osteoporosis patients. A network meta‑analysis of over 80,000 participants found that parathyroid hormone receptor agonists such as abaloparatide reduced clinical and vertebral fractures more effectively than bisphosphonates, though the certainty of the estimates was moderate to low. A living systematic review reported that abaloparatide lowered clinical and radiographic vertebral fracture rates but was associated with a higher frequency of withdrawals due to adverse events. Recent therapeutic overviews list abaloparatide among the available osteoanabolic options for postmenopausal osteoporosis.
Reported Benefits
Evidence indicates that abaloparatide can reduce the risk of clinical fractures and vertebral fractures more than anti‑resorptive agents like bisphosphonates, especially in patients at very high fracture risk. Its anabolic action leads to gains in bone mineral density, supporting its use as a first‑line anabolic therapy for severe osteoporosis.
Limitations of the Evidence
The comparative effectiveness data are of moderate to low certainty, with limited long‑term follow‑up beyond 24 months. Few trials have included men, individuals with low bone mass rather than established osteoporosis, or diverse racial groups. Increased withdrawals due to adverse events have been reported, and the optimal sequencing with other osteoporosis drugs remains under investigation.
Safety Considerations
Clinical trials have shown that abaloparatide is generally well tolerated but is linked to a higher rate of treatment discontinuation because of adverse events. No specific serious safety signals were identified in the meta‑analyses, yet clinicians should monitor patients for typical PTH‑analogue side effects and consider individual risk factors before prescribing.
How It Is Administered
Abaloparatide is administered by subcutaneous injection and is available only by prescription. It is supplied in a pre‑filled device for self‑injection and is used according to the dosing regimen approved by regulatory agencies.
Routes of Administration
Goals & Uses
- Treatment of male osteoporosisBone HealthModerate
- Reduction of vertebral fracture riskBone HealthHigh
- Increase in bone mineral density (BMD)Bone HealthHigh
- Reduce vertebral fracture riskEfficacyHigh
- Anabolic bone therapy before antiresorptive treatmentBone HealthModerate
- Increase bone mineral densityBone HealthHigh
- Reduction of nonvertebral fracture riskBone HealthHigh
Contraindications
- Hypersensitivity to abaloparatide or any excipientAllergyHigh
- Prior external beam or implant radiation therapy to the skeletonRadiation HistoryHigh
- Pediatric patients or open epiphysesAge/developmentalHigh
- HypercalcemiaMetabolic DisorderHigh
- Bone metastases or skeletal malignancyOncologyHigh
- Paget's disease of boneBone DisorderHigh
- Prior radiation therapy to the skeletonSkeletalModerate
- Paget disease of boneSkeletalModerate
- Metabolic bone diseases other than osteoporosis (e.g., Paget disease, osteitis deformans)Bone DiseaseModerate
Adverse Effects
- HypercalcemiaMetabolicCommon
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- HypercalciuriaMetabolicCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Injection‑site reactionsLocalCommon
- OsteosarcomaOncologyRare
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
- Orthostatic hypotension/dizzinessCardiovascularCommon
Drug Interactions
- BisphosphonatesModerate
- Antiresorptive agents (bisphosphonates, denosumab)Low
- Calcium supplements / Vitamin DLow
- Calcium supplementsModerate
- Thiazide diureticsModerate
Population Constraints
- PregnancyReproductive SafetyAbsolute
- Pediatric patientsAgeAbsolute
- LactationReproductiveRelative
- Prior osteosarcoma or high-risk bone conditionsOncologyAbsolute
- Pregnant or breastfeeding womenReproductiveAbsolute
- Renal impairment (severe, CrCl <30 mL/min)RenalRelative
- Severe renal impairment (eGFR <30 mL/min)RenalRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization as of 2024
- United StatesApprovedApproved: Postmenopausal osteoporosisApproved 2017; brand name Tymlos
- United KingdomUnapprovedFollows EU status
Approved by the US FDA in 2017 (brand name Tymlos) for osteoporosis; not approved in the EU as of 2024.
Evidence & Sources
- Journal ArticleModerateMorin SN, Leslie WD, Schousboe JT2025-01-01T00:00:00.000000Z
- Journal ArticleHighHändel MN, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateSølling AS, Langdahl BL, Cosman F2026-01-01T00:00:00.000000Z
- Journal ArticleHighAyers C, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateJohnston CB, Dagar M2020-01-01T00:00:00.000000Z
Frequently Asked Questions
Who is a candidate for abaloparatide therapy?
Abaloparatide is recommended for adults with osteoporosis who are at very high risk of fracture, such as those with recent vertebral fractures, a hip fracture with a T‑score ≤ ‑2.5, or multiple prior fractures, according to clinical reviews.
How does abaloparatide differ from bisphosphonates?
Unlike bisphosphonates, which mainly inhibit bone resorption, abaloparatide stimulates bone formation by activating the PTH1 receptor intermittently, leading to greater increases in bone density and fracture risk reduction in high‑risk patients.
What are the main safety concerns with abaloparatide?
Clinical evidence notes a higher incidence of treatment discontinuation due to adverse events compared with placebo, though serious safety issues were not identified. Patients should be monitored for typical side effects of PTH analogues and any new symptoms.
Can abaloparatide be used after other osteoporosis treatments?
Guidelines suggest that anabolic agents like abaloparatide may be used before or after anti‑resorptive therapy to maximize bone gain, but the optimal sequencing and duration require individualized assessment and further study.
Is abaloparatide suitable for men with osteoporosis?
Current trial data focus largely on postmenopausal women; evidence for efficacy and safety in men is limited, highlighting a gap in the existing literature.
What is Abaloparatide?
Abaloparatide is a prescription, subcutaneously administered analogue of parathyroid hormone‑related protein (PTHrP) approved for the treatment of osteoporosis. It belongs to the class of bone‑forming (anabolic) agents and is recommended for individuals at very high risk of fracture, such as those with recent vertebral fractures or low bone mineral density.
What is Abaloparatide used for?
Abaloparatide is educationally associated with: Treatment of male osteoporosis, Reduction of vertebral fracture risk, Increase in bone mineral density (BMD), Reduce vertebral fracture risk, Anabolic bone therapy before antiresorptive treatment, Increase bone mineral density, Reduction of nonvertebral fracture risk. Educational only — not medical advice.
How is Abaloparatide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Abaloparatide?
Reported adverse effects include: Hypercalcemia, Injection site reactions, Headache, Hypercalciuria, Nausea, Injection‑site reactions, Osteosarcoma, Dizziness, Orthostatic hypotension/dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Abaloparatide?
Recorded contraindications: Hypersensitivity to abaloparatide or any excipient, Prior external beam or implant radiation therapy to the skeleton, Pediatric patients or open epiphyses, Hypercalcemia, Bone metastases or skeletal malignancy, Paget's disease of bone, Prior radiation therapy to the skeleton, Paget disease of bone, Metabolic bone diseases other than osteoporosis (e.g., Paget disease, osteitis deformans). Consult a qualified clinician before use.